082615 Combination inhalers for upper airway diseases – oral inhalers containing two drugs that compliment the therapeutic actions of one another – have seen a significant increase in development activity and product proliferation in the past five years. This growth is due to improved patient experience from improved ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are showing significant commercial success in the two markets for which they are indicated – Asthma and COPD – both of which are forecast to grow at impressive rates for the remainder of the decade.
In the area of inhaler technology, MES has the exclusive worldwide rights to sell one of the most innovative DPIs available today, the DoseOne™ Single Dose Powder Inhaler. Development of the DoseOne™ single dose powder inhaler (US Patent #7,832,399 B2 and #8,360,057 B2) required a multi-disciplinary team approach, as any such drug delivery device needs to combine not just design skills, but also software and mechanical engineering capabilities, and expertise in analytical science and industrialisation. MES worked on the DoseOne™ device from concept creation, allowing the design to be sympathetic to the requirements for mass manufacture and regulatory compliance.
The DoseOne™ is equipped with a simple dose readiness indicator and a dose delivery indicator — which means it conforms with strict FDA patient-compliance regulations previously only attained by expensive MDIs and multi-use DPIs. DoseOne™ is a perfect example of what can be achieved if an innate understanding of micro manufacturing design and manufacturing is combined with an understanding of the regulatory environment that exists around drug delivery devices these days, and a realisation of the potential for innovative solutions that cater for mass “self” administration of drugs in a cost effective and safe way.
If you are a pharma manufacturer out there looking to locate a novel, cost-effective, and efficient drug delivery option, please email Donna Bibber at [email protected] For full details of DoseOne™ see www.dose-one.com.